SAN

76.28

+1.88%↑

ARGX

681.2

+2.41%↑

SHL.DE

33.91

-0.24%↓

FRE

39.73

+0.76%↑

PHIA

22.78

+1.2%↑

SAN

76.28

+1.88%↑

ARGX

681.2

+2.41%↑

SHL.DE

33.91

-0.24%↓

FRE

39.73

+0.76%↑

PHIA

22.78

+1.2%↑

SAN

76.28

+1.88%↑

ARGX

681.2

+2.41%↑

SHL.DE

33.91

-0.24%↓

FRE

39.73

+0.76%↑

PHIA

22.78

+1.2%↑

SAN

76.28

+1.88%↑

ARGX

681.2

+2.41%↑

SHL.DE

33.91

-0.24%↓

FRE

39.73

+0.76%↑

PHIA

22.78

+1.2%↑

SAN

76.28

+1.88%↑

ARGX

681.2

+2.41%↑

SHL.DE

33.91

-0.24%↓

FRE

39.73

+0.76%↑

PHIA

22.78

+1.2%↑

Home・Akcijų sąrašas・Fagron

Fagron

Atidarymo kaina

SektoriusSveikatos priežiūra

24.25 0.83

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23.9

Max

24.25

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-99K 45M
Pardavimai	-98K 476M
P/E Sektoriaus vid.	19.597 49.701
Dividendų pajamingumas	1.66
Pelno marža	9.55
Darbuotojai	4,193
EBITDA	11M 98M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+20.59% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	1.66% 2.39%
Kitas uždarbis	2026-07-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	153M 1.8B
Ankstesnė atidarymo kaina	23.42
Ankstesnė uždarymo kaina	24.25

Naujienos nuotaikos

By Acuity

50%

174 / 345 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-19 20:36; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

2026-05-19 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

2026-05-19 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026-05-19 23:28; UTC

Rinkos pokalbiai

Uždarbis

Global Forex and Fixed Income Roundup: Market Talk

2026-05-19 23:28; UTC

Rinkos pokalbiai

Uždarbis

F&P Healthcare's Outlook Key for Investors -- Market Talk

2026-05-19 23:10; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-19 23:10; UTC

Rinkos pokalbiai

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

2026-05-19 22:02; UTC

Uždarbis

ZTO Express (Cayman): Di Xu to Resign From Board

2026-05-19 22:01; UTC

Uždarbis

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

2026-05-19 22:01; UTC

Uždarbis

ZTO Express (Cayman) 1Q EPS 39c >ZTO

2026-05-19 22:00; UTC

Uždarbis

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

2026-05-19 21:37; UTC

Uždarbis

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

2026-05-19 21:31; UTC

Įsigijimai, susijungimai, perėmimai

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

2026-05-19 21:01; UTC

Uždarbis

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

2026-05-19 20:58; UTC

Uždarbis

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

2026-05-19 20:46; UTC

Karštos akcijos

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

2026-05-19 20:43; UTC

Rinkos pokalbiai

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

2026-05-19 20:34; UTC

Uždarbis

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries 4Q EPS 5c >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries 4Q Sales $1.4B >JHX

2026-05-19 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Buy Empower Semiconductor for $1.5B

2026-05-19 20:18; UTC

Rinkos pokalbiai

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

2026-05-19 20:13; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-19 20:13; UTC

Rinkos pokalbiai

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

2026-05-19 20:03; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

2026-05-19 20:03; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

2026-05-19 20:02; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

2026-05-19 20:02; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

2026-05-19 19:23; UTC

Rinkos pokalbiai

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR 20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Fagron akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

174 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.